Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Posted: August 22, 2022 at 2:55 am

Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced the signing of an agreement with YA II PN, Ltd, an exempted company incorporated in the Cayman Islands with limited liability, a company of the group of companies managed by Yorkville Advisors Global LP, its investment manager ("Yorkville"), for a financing via the issuance of convertible notes of up to CHF 20 million, to be drawn in tranches.

Continued here:
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Related Posts